Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2201612 | 1.00 | ALDH1A1 (0.58) | ALDH1A1CYP1A2CYP2A6TSHRLMNA | |
| SCHEMBL10426802 | 1.00 | ALDH1A1 (0.58) | ALDH1A1CYP1A2CYP2A6TSHRLMNA | |
| SCHEMBL5772875 | 0.85 | ALDH1A1 (0.48) | ALDH1A1LMNAJAK2CYP3A4JAK1 | |
| SCHEMBL19900000 | 0.85 | ALDH1A1 (0.48) | ALDH1A1POLBTYK2HTR2AHTR2C | |
| SCHEMBL29387927 | 0.85 | ALDH1A1 (0.48) | ALDH1A1LMNAJAK2CYP3A4JAK1 | |
| SCHEMBL11893724 | 0.85 | ALDH1A1 (0.48) | ALDH1A1LMNAJAK2CYP3A4JAK1 | |
| SCHEMBL11911197 | 0.85 | ALDH1A1 (0.48) | ALDH1A1LMNAJAK2CYP3A4JAK1 | |
| SCHEMBL19899998 | 0.85 | ALDH1A1 (0.48) | ALDH1A1POLBTYK2HTR2AHTR2C | |
| SCHEMBL23277213 | 0.80 | TYK2 (0.46) | ALDH1A1CYP3A4TYK2SMN1; SMN2MEN1 | |
| SCHEMBL22789943 | 0.80 | CA1 (0.44) | ALDH1A1TSHRLMNAHPGDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262799-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2024-08-08 | — | — | US | disclosed |
| US-11912674-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-20230357244-A1 | FXR SMALL-MOLECULE AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357244-A1 | FXR SMALL-MOLECULE AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230295141-A1 | FXR SMALL MOLECULE AGONIST, THE PREPARATION AND USE THEREOF | CASCADE PHARMACEUTICALS, INC. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295141-A1 | FXR SMALL MOLECULE AGONIST, THE PREPARATION AND USE THEREOF | CASCADE PHARMACEUTICALS, INC. (CN) | 2023-09-21 | — | — | US | disclosed |
| EP-4245365-A1 | A FXR SMALL MOLECULE AGONIST, THE PREPARATION AND USE THEREOF | Cascade Pharmaceuticals, Inc. (CN) | 2023-09-20 | — | — | EP | disclosed |
| US-11718619-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | ARDELYX, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718619-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | ARDELYX, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230139597-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2004099164-A1 | SUBSTITUTED DIPHENYL ISOXAZOLES, PYRAZOLES AND OXADIAZOLES USEFUL FOR TREATING HCV INFECTION | RIGEL PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004099165-A2 | HETEROCYCLIC COMPOUNDS AND HYDRO ISOMERS THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| EP-1451162-A1 | SUBSTITUTED DIPHENYL HETEROCYCLES USEFUL FOR TREATING HCV INFECTION | Rigel Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20040142985-A1 | Heterocyclic compounds useful to treat HCV | RIGEL PHARMACEUTICALS | 2004-07-22 | — | — | US | disclosed |
| US-6759538-B2 | PREVENTION INFECTIONS OF HEPATITIS C VIRUS | RIGEL PHARMACEUTICALS, INC. | 2004-07-06 | — | — | US | disclosed |
| US-20030165561-A1 | Substituted diphenyl heterocycles useful for treating HCV infection | MIDCAP FINANCIAL TRUST | 2003-09-04 | — | — | US | disclosed |
| WO-2003040112-A1 | SUBSTITUTED DIPHENYL HETEROCYCLES USEFUL FOR TREATING HCV INFECTION | RIGEL PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| EP-0314422-B1 | N-PHENYLALKYLBENZAMIDE FUNGICIDES | DOWELANCO (US) | 1993-07-28 | — | — | EP | disclosed |
| US-4957533-A | THIOAMIDES, AMIDINES | ELI LILLY AND COMPANY (US) | 1990-09-18 | — | — | US | disclosed |
| EP-0314422-A2 | N-phenylalkylbenzamide fungicides | DOWELANCO (US) | 1989-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142985-A1 | Heterocyclic compounds useful to treat HCV | HAVCR2, PCNA, HCCS | ALDH1A1 1236/4885CYP1A2 1370/4885CYP2A6 1426/4885 |
| US-11718619-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | FXR1, FXR2, NR1H4 | ALDH1A1 968/4885CYP1A2 310/4885CYP2A6 493/4885 |
| US-20230295141-A1 | FXR SMALL MOLECULE AGONIST, THE PREPARATION AND USE THEREOF | FXR1, NR1H4, FXR2 | ALDH1A1 2240/4885CYP1A2 168/4885CYP2A6 301/4885 |
| US-20230139597-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | ALDH1A1 2057/4885CYP1A2 504/4885CYP2A6 327/4885 |
| US-20230357244-A1 | FXR SMALL-MOLECULE AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | FXR1, NR1H4, FXR2 | ALDH1A1 2161/4885CYP1A2 317/4885CYP2A6 464/4885 |
| US-20240262799-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H3, NR1H2 | ALDH1A1 1135/4885CYP1A2 195/4885CYP2A6 286/4885 |
| US-11912674-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | NR1H4, NR1H3, NR1H2 | ALDH1A1 840/4885CYP1A2 203/4885CYP2A6 384/4885 |
| US-20030165561-A1 | Substituted diphenyl heterocycles useful for treating HCV infection | HAVCR2, HCCS, PCNA | ALDH1A1 984/4885CYP1A2 1064/4885CYP2A6 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.